SC raps Centre, states for 'apathy' in handling leprosy

Image
Press Trust of India New Delhi
Last Updated : Nov 28 2014 | 5:20 PM IST
The Supreme Court today rapped the Centre and states for their "apathy" in eradicating leprosy from the country, saying despite it being "curable" the disease still remains a stigma.
A bench of justices Dipak Misra and U U Lalit, which had earlier issued notices in the matter, expressed displeasure when the counsel for the Centre and some state governments sought time to file their responses.
"We have granted four weeks time. This is a case which should have been taken on priority basis. Leprosy, as on today, is curable and yet because of apathy shown by the authorities concerned, it still remains as a stigma," the court said.
It asked the Centre and others to file their replies within four weeks, saying "no further adjournments will be granted in the case."
Earlier, the court had expressed concern over prevalence of the disease and had issued notices to the Centre and the States on the PIL filed by lawyer Pankaj Sinha.
The plea alleged that leprosy affects over 1.25 lakh people annually in the country.
Sinha alleged that governments have failed to eliminate the disease despite medical treatment available since 1981.
"Despite an effective cure, namely Multi-Drug Therapy (MDT), which has been available since 1981, that can completely cure 99 per cent of leprosy bacteria, due to apathy of the Government of India and the State Governments, people are still suffering from the said disease, which is treated as a social stigma," the petition said.
The plea has sought a direction to the governments that drugs be made available at primary health centres in the country
It also pleaded that appropriate scheme be formulated to bring people suffering from leprosy into national mainstream.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 28 2014 | 5:20 PM IST

Next Story